BEHIND THE NEWS: Lechleiter went toe to toe with Icahn to cut megadeal
Eli Lilly and Co. had been salivating over ImClone Systems Inc. for more than two years when, on July 25 of this year, its senior executives received a formal staff recommendation to contact the company and make an overture. So it must have come as quite a jolt to Lilly brass when, just six days later, Bristol-Myers Squibb announced that it was offering to buy the 83 percent of ImClone it didn’t already own for $60 a share, or $4.5…